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The monitoring of the levels of alloantibodies following
transplantation might facilitate early diagnosis of chronic
rejection (CR), the leading cause of renal allograft failure.
Here, we used serial alloantibody surveillance to monitor
patients with preoperative positive flow cytometric
crossmatch (FCXM). Sixty-nine of 308 renal transplant
patients in our center had preoperative positive FCXM. Blood
was collected quarterly during the first postoperative year
and tested by FCXM and single antigen bead luminometry,
more sensitive techniques than complement-dependent
cytotoxic crossmatching. Distinct post-transplant profiles
emerged and were associated with different clinical
outcomes. Two-thirds of patients showed complete
elimination of FCXM and solid-phase assay reactions within
1 year, had few adverse events, and a 95% 3-year graft
survival. In contrast, the remaining third failed to eliminate
flow FCXM or solid-phase reactions directed against HLA
class I or II antibodies. The inferior graft survival (67%)
with loss in this latter group was primarily due to CR.
Thus, systematic assessment of longitudinal changes in
alloantibody levels, either by FCXM or solid-phase assay,
can help identify patients at greater risk of developing CR.
Kidney International (2011) 79, 1131–1137; doi:10.1038/ki.2010.556;
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Despite improvements in short-term renal allograft outcome,
long-term graft survival is unchanged, with chronic rejection
(CR) remaining the leading cause of graft failure.
1–4
Compelling evidence indicates that circulating alloantibody
against donor HLA antigens contributes to the process of CR.
For this reason, patients elaborating alloantibody before
transplant generally exhibit poorer graft survival than
nonsensitized individuals.
5–13 Post-transplant detection of
alloantibody is associated with a higher incidence of
CR,
4,14–23 and circulating alloantibody is found in most
patients at the time of graft failure.
4–5,16,19–20,23–26
It is believed that post-transplant monitoring of alloantibody
might facilitate early diagnosis of CR. Unfortunately, a
paradigm for effective monitoring has not been established
and the burden of developing a protocol falls upon individual
laboratories. It is not clear which patients should be monitored,
when they should be monitored, what techniques are most
informative, or what alloantibody parameters are markers for
CR. A systematic longitudinal assessment of post-transplant
changes in alloantibody among unselected patients is needed.
Beginning in 2005, we initiated a prospective study to
address some of these issues. Because patients with
preoperatively positive ﬂow cytometric crossmatch (FCXM)
have always had poorer graft survival at this center, we
developed a surveillance template to follow them exclu-
sively.
6,27 Blood was collected quarterly during the ﬁrst year
after transplant and alloantibody determined using FCXM
and solid-phase assay. Post-transplant antibody changes were
correlated with the 3-year clinical outcome.
This report summarizes our cumulative ﬁndings of long-
itudinal changes in alloantibody proﬁles among patients with
preoperatively positive FCXM. We observed two distinct post-
transplant proﬁles: complete versus no elimination of alloanti-
body. However, only the latter proﬁle was associated with
development of CR and poorer graft survival. Identiﬁcation of
acceptable and nonacceptable post-transplant alloantibody
proﬁles should help stratify patients in terms of the risk for
developing CR and promote early diagnosis.
RESULTS
Patients
Patients were ﬁrst partitioned on the basis of whether
preoperative FCXM was negative or positive. Patient
demographics were similar (Table 1). Both groups were
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deceased donors. Age and gender distributions were equiva-
lent. Both were poorly HLA matched with donors. The Tand
B panel-reactive antibodies were higher among the FCXM-
positive group. In all, nine patients had positive FCXM
because of non-HLA antibodies and were excluded from
subsequent analysis. All remaining patients with positive
FCXM showed donor-speciﬁc antibody (DSA) and non-DSA.
Post-transplant alloantibody profiles. Two post-transplant
antibody proﬁles were observed. The majority of patients
(group I, 65%) showed complete elimination of FCXM
reactivity within the ﬁrst postoperative year (Figure 1a–c).
The T- and B-FCXM levels were equivalent preoperatively
and at all time points (P¼0.4). Both T- and B-FCXM
reactivity became negative in 71% patients by month 6 and
100% by month 12. Reductions in FCXM levels were
mirrored using single antigen bead identiﬁcation of DSA
and non-DSA. Pretransplant DSA was exclusively directed
against class I or II in 66 and 34% of patients. Pretransplant
DSA levels were equivalent against class I and II (P¼0.06).
DSA levels against class I and II declined 90% by month 6
and were undetectable by month 12. To estimate a total level
of non-DSA, all individual mean ﬂuorescent intensities were
combined into a single value for each patient. Pretransplant
non-DSA against class I or II were found in 60 and 50% of
patients. Total pretransplant levels of non-DSA against class I
and II were greater than DSA levels (Po0.001) and
predominantly directed against class I (Po0.001). Total
non-DSA mean ﬂuorescent intensity levels against class I
and II were reduced 50–70% by month 6 and 80–90% by
month 12.
Three patients had proﬁles and clinical outcome similar to
group I but failed to completely eliminate DSA against class I
by month 12. Although they are probably a subgroup of
group I in which antibody elimination proceeds more slowly,
we eliminated them from subsequent analysis because of
their small size and nonidentical proﬁle.
Post-transplant antibody proﬁles for the remaining
patients (group II) differed markedly from group I (Figure
1d–f). Group II failed to eliminate or show signiﬁcant
reductions in FCXM, DSA, or non-DSA levels against class I
or II during the ﬁrst post-transplant year. Preoperative T- and
B-FCXM levels were equivalent (P¼0.4). Despite transient
ﬂuctuations in T-FCXM levels, the levels subsequently
rebounded. B-FCXM levels were unchanging throughout
the ﬁrst year. Solid-phase testing showed a similar pattern
of alloantibody persistence. Preoperative DSA against class I
or II were found in 60 and 40% of patients. DSA levels
against both class I and II were unchanged throughout the
year. Preoperative non-DSA against class I or II were found in
60 and 60% of patients and levels were signiﬁcantly greater
than DSA levels (Po0.001). Non-DSA levels against class I
and II declined 23 and 52% by month 6. However, by month
12, reactivity against class I and II was either unchanged
or increased. Total non-DSA levels against class I and II were
signiﬁcantly greater among group II than group I by month
12 (Po0.001).
Comparison of pretransplant antibody characteristics
Once groups were identiﬁed based upon post-transplant
alloantibody elimination proﬁles, we re-evaluated preopera-
tive antibody characteristics hoping to identify features
that would predict post-transplant antibody developments.
Unfortunately, none were found. The group demographics
were equivalent. The donor characteristics were equivalent
(Table 2). Panel-reactive antibody distribution was equivalent
with most patients showing sensitization (Table 3). T- and
B-FCXM levels were equivalent between and within groups.
All patients had DSA and non-DSA. DSA frequency (1 to 2
per patient) was equivalent between groups. DSA distribu-
tion was equivalent between groups and was directed against
class I among 60–70% of patients or class II among 30–40% of
patients. Few patients had DSA against both class I and II and
most patients had only one DSA. DSA levels against class I
and II were equivalent between groups. Although subjective,
we consider DSA mean ﬂuorescent intensity as low (o1000),
moderate (1000–5000), or high (45000) strength. Thus,
patients had moderate to high alloantibody strengths in both
groups. The frequency of non-DSA (7±3) directed against
class I or II was similar between groups. Total non-DSA levels
against class I were equivalent between groups and greater
than against class II (Po0.001). The only overt difference was
the elevated non-DSA levels against class II in group II
relative to group I (P¼0.001).
Clinical outcome
Patient and graft survival were compared between groups and
patients with preoperatively negative FCXM. The 3-year
actuarial patient survival was equivalent (P¼0.5) between
FCXM-negative patients (99%) and groups I (100%) and II
(100%). In contrast, the 3-year actuarial graft survival
differed (Figure 2). Graft survival was equivalent between
FCXM-negative patients (96%) and group I (95%, P¼0.5)
but poorer among group II (67%, Po0.001).
Additional clinical outcome parameters were compared
(Table 4). The frequency of acute cellular rejection was low
Table 1|Demographics of patients with preoperatively
positive or negative FCXM
FCXM negative FCXM positive P-value
n 239 69
Ethnicity
African American 70% 80% 0.1
Caucasian 30% 20% 0.1
Female/male 56/44% 51/49% 0.3
First grafts 89% 89% 0.9
Deceased donor 72% 80% 0.2
Age (years) 47±14 3 ±5 0.3
ABDR MM 4.8±0.5 5.0±0.6 0.5
T-PRA 22±29% 50±37% 0.01
B-PRA 14±30% 39±39% 0.03
Abbreviations: ABDR MM, HLA antigen ABDR mismatch, FCXM, flow cytometric
crossmatch; PRA, panel-reactive antibody.
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greater among group II (21%, Po0.001). Antibody-mediated
rejection (AMR) was minimal (p3%) among FCXM-
negative patients and group I but prevalent among group II
(43%, Po0.001). Rejection severity and timing to diagnosis
of AMR was equivalent between all groups. Although AMR
occurred later than in many studies, the delay may be related
to our use of thymoglobulin induction in all patients as well
as maintaining high levels of tacrolimus and mycophenolate
mofetil. Diagnosis of CR was low among FCXM-negative
patients and group I. In contrast, CR was prevalent among
group II (43%, Po0.001) and responsible for 80% of graft
failures versus 0% in other groups. Although mean serum
creatinine at 1 year was greater among group II (Po0.01),
there was considerable overlap with the ranges seen among
FCXM-negative patients and group I.
Despite alloantibody persistence, only half of group II
experienced AMR and CR within the study interval. The
remainder stayed AMR and CR free. A comparison of
pretransplant alloantibody characteristics showed no obvious
differences in FCXM, DSA, or non-DSA levels between the
subgroups (Table 5). Acute cellular rejection occurred with
equal frequency between the subgroups (25 vs 20%, P¼0.1).
However, group II patients without AMR enjoyed the 3-year
graft survival equivalent to group I (100 vs 97%, P¼0.9).
DISCUSSION
There is strong evidence that anti-HLA antibodies contribute
to the development of CR, the leading cause of renal allograft
failure.
1,2,4–5,10,14–15,17–18,23–29 While it is hoped that post-
transplant alloantibody surveillance might facilitate early
diagnosis, there are few guidelines regarding how monitoring
should be performed and results interpreted. This report
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Figure 1|Longitudinal assessment of changes in flow cytometric crossmatch (FCXM), donor-specific antibody (DSA), and non-DSA
levels during the first post-transplant year. Blood collected quarterly among patients with preoperatively positive FCXM was tested by
FCXM and single antigen bead luminometry. Nine patients with FCXM reactivity but lacking anti-HLA specificity and three patients with
atypical group I profile were excluded from consideration. Group I (n¼33) showed complete elimination of FCXM, DSA, and non-DSA
within 12 months. Group II (n¼15) maintained FCXM, DSA, and non-DSA levels against class I and II throughout the study interval. FCXM
symbols: J T-FCXM channel shifts; K B-FCXM channel shifts. DSA and non-DSA symbols: ’ anti-class I mean fluorescent intensity (MFI);
m anti-class II MFI. Group I: (a) FCXM channel shifts±s.d.; (b) DSA MFI±s.d.; and (c) non-DSA MFI±s.d. Group II: (d) FCXM channel
shifts±s.d. (e); DSA MFI±s.d.; and (f) non-DSA MFI±s.d.
Table 2|Patient and donor characteristics between groups I
and II
Group I Group II P-value
1. Days on dialysis 1497±1283 1738±1510 0.6
2. Type of donor
Living 15% 33% 0.1
Standard criteria 78% 47% 0.03
Expanded criteria 2% 7% 0.4
Donation after cardiac death 5% 13% 0.3
3. Cold ischemia time (min) 913.1±617.1 728.9±507.9 0.3
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PM Kimball et al.: Post-transplant alloantibody surveillance original articlesummarizes our experience in attempting to develop a
utilitarian and clinically informative monitoring paradigm by
correlating clinical outcome with longitudinal changes in
FCXM and solid-phase assay reactivity occurring during the
ﬁrst post-transplant year. We intentionally excluded patients
with preoperatively negative FCXM who typically experience
excellent graft survival and minimal CR.
6–7,12,16 We also
excluded nine patients with preoperatively positive FCXM
because of non-HLA antibodies and a small subgroup of
group I (n¼3) with slower antibody elimination. Instead, we
focused our attention upon patients with preoperatively
positive FCXM because of preformed anti-HLA antibody
who, at this center, have poorer graft survival.
6,27 Changes in
speciﬁcity techniques throughout the years made original
speciﬁcity data incomparable. To standardize the data, we
reassayed patient serum for anti-HLA speciﬁcities using one
lot of single antigen beads on a Luminex platform and also
retested donor HLA for minor histocompatibility antigens
not determined originally. Consistent with a recent report,
the enhanced sensitivity of single antigen bead testing
allowed identiﬁcation of DSA and non-DSA in 100% of
study patients.
30
Temporal changes in alloantibody levels were consistent
whether measured using FCXM or solid-phase assay. Two
post-transplant proﬁles emerged and showed different
clinical outcomes. Patients showing complete elimination of
alloantibody enjoyed excellent graft survival and few
complications. In contrast, patients failing to eliminate
alloantibody had poorer outcomes and higher incidence of
Table 3|Pretransplant antibody comparison between groups
Group I Group II
(1) n 33 15
(2) T-PRA
o10% 26% 35%
11–80% 33% 41%
480% 41% 34%
(3) B-PRA
o10% 67% 75%
11–80% 26% 17%
480% 7% 8%
(4) FCXM channel shifts±s.d.
T-FCXM 104±9 127±88
B-FCXM 101±70 118±74
(5) Number of patients with DSA
Class I
1 DSA 61% 47%
41 DSA 6% 13%
Class II
1 DSA 34% 27%
41 DSA 0% 13%
(6) DSA MFI±s.d.
Class I 3830±1450 5773±1081
Class II 2607±1304 4800±536
(7) Number of patients with non-DSA
Class I 48% 40%
Class II 45% 33%
(8) Total non-DSA MFI±s.d.
Class I 75,248±23,342 85,917±44,500
Class II 14,609±9784
a 38,116±15,591
a,b
Abbreviations: DSA, donor-specific antibody; FCXM, flow cytometric crossmatch;
MFI, mean fluorescent intensity; PRA, panel-reactive antibody.
Patients were divided into groups based upon post-transplant alloantibody
elimination profiles. Nine patients with FCXM reactivity because of non-HLA
antibodies and 3 patients with atypical group I profile were excluded from
consideration. FCXM and single antigen bead testing on Luminex platform were
performed as described in the text. Most patients had only one class I or II DSA. In
the few patients with two DSAs against either class I or II, the MFI is the strength
index of the immunodominant specificity instead of the cumulative strength. In
contrast, total non-DSA antibody burden was calculated by combining all non-DSA
MFIs into a single value for each patient. Unless otherwise indicated, data between
and within groups were statistically equivalent (P40.5). Preoperative DSA testing
was performed upon patients with negative FCXM, but no DSAs were identified with
the technologies used at that time.
aPo0.001, total non-DSA MFI greater against class I than II.
bP=0.001, total non-DSA MFI against class II greater in group II than I.
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Figure 2|Actuarial graft survival. Deaths with functioning
grafts were censored. ’ Patients with preoperatively negative
flow cytometric crossmatch (FCXM; n¼239); m Group I; . Group II.
Po0.001, graft survival among group II versus group I.
Table 4|Comparison of the 3-year clinical outcomes
FCXM-neg Group I Group II
n 239 33 15
ACR 4% 5% 21%*
AMR 1% 3% 43%*
Banff I 66% 60% 55%
Banff II 33% 30% 33%
Banff III 0% 10% 11%
Months to AMR 17±13 14±51 3 ±3
CR 1% 0% 43%*
Graft failure 3% 5% 33%*
Failure due
To CR 0% 0% 27%*
Death 1% 0% 0%
1-year sCr (mg/dl) 1.4±0.7 1.5±0.5 2.9±3.1*
Range 0.7–8.6 0.8–2.9 0.6–9.5
Abbreviations: ACR, acute cellular rejection; AMR, antibody-mediated rejection;
CR, chronic rejection; FCXM, flow cytometric crossmatch; sCr, serum creatinine.
Patients were initially partitioned based upon preoperative FCXM reactivity.
The preoperatively positive FCXM patients were then regrouped based upon
post-transplant alloantibody elimination profiles. Patients with positive FCXM due to
non-HLA antibodies and an atypical subgroup of group I were excluded. Clinical
outcome was determined from chart review.
*Po0.001, group II vs group I and FCXM-negative patients.
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antibody characteristics were compared with the hope that
some distinguishing parameters would predict post-trans-
plant outcome. However, similar to previous reports,
pretransplant characteristics proved inadequate indicators
of post-transplant developments.
8,10,13 Before transplant,
groups were equivalent in terms of demographics, donor
characteristics, alloantibody levels, and speciﬁcities. Alloanti-
bodies against class I predominated in all groups. However,
group II did show a greater total amount of non-DSA against
class II than group I.
It has always been puzzling why only a fraction of
presensitized patients actually develop CR.
6–10,16,19–20 Our
surveillance study provides a partial explanation. The
majority of patients (65%) showed rapid reduction of both
T- and B-FCXM levels within 6 months of transplant and
complete elimination within 12 months. These results were
mimicked using solid-phase testing that showed that DSAs
and non-DSAs against class I and II were simultaneously
eliminated. Elimination of circulating alloantibody trans-
formed this group into a FCXM-negative population that
typically has excellent long-term graft survival and minimal
CR. The cause of antibody elimination is unknown. However,
one possible mechanism could be downregulation of anti-
body synthesis after transplantation. Considering the short
half-life of immunoglobulin G, complete depletion of
circulating alloantibody within 6–12 months is entirely
possible if synthesis stopped soon after transplantation.
Simultaneous depletion of DSA and non-DSA suggests that
the effect is global and not speciﬁc to DSAs. Alternatively,
alloantibody binding to the graft could artiﬁcially lower
circulating levels below detection thresholds of assays.
However, as this would not explain the simultaneous
elimination of non-DSAs unless they also bound to the
graft, we believe the ﬁrst possibility is the more likely
mechanism.
The second post-transplant proﬁle identiﬁed a group that
failed to eliminate FCXM, DSA, or non-DSA reactivity
against class I and II within the ﬁrst postoperative year.
Persistence of circulating alloantibody predisposed this group
for a higher risk of AMR and CR and ultimately poorer graft
survival. The critical question is why is the alloantibody not
eliminated among group II as occurred among group I?
Unfortunately, we do not have an answer. Group II did not
demonstrate any unique antibody characteristics before
transplant. However, group II demonstrated several unique
post-transplant differences that either individually or collec-
tively may predispose this group for CR. First, only group II
failed to eliminate alloantibody, which suggests that activa-
tion of downregulatory pathways are inhibited in this group.
Second, only group II was unable to eliminate DSAs directed
against class I and II. Numerous studies show that circulating
DSA against either class I or II are deleterious to graft
survival. Some studies have suggested that anti-class II DSAs
may more aggressively promote CR than anti-class I.
10,15
Thus, the perseverance of anti-class II among group II may
enhance the chances of developing CR. Third, only group II
was unable to eliminate non-DSA directed against class I and
II and maintained signiﬁcantly high levels of non-DSA
against class I and II. The precise role of non-DSAs in
allograft survival is unclear but there is growing evidence that
they may contribute to allograft destruction by crossreactive
recognition of shared epitopes on the allograft. If this
occurred among group II, then the high cumulative burden
of non-DSA levels combined with sustained DSA levels may
escalate the probability of CR.
Interestingly, despite alloantibody persistence, nearly half
of group II remained AMR and CR free and had excellent
graft outcome. This is consistent with the historic inability to
show 100% causal relationship between detection of
circulating alloantibody and active disease. Because pretrans-
plant alloantibody characteristics were equivalent between
these subgroups (as well as group I), they were useless in
forecasting post-transplant antibody proﬁles or clinical
outcomes. Our data suggest that (1) alloantibody persistence
is not an automatic trigger for AMR and (2) AMR without
antibody persistence is not an automatic trigger for CR
(group I patients with AMR have not yet demonstrated CR).
Our interpretation is that alloantibody persistence during the
ﬁrst year heightens the risk of AMR. However, alloantibody
alone is an insufﬁcient trigger for AMR. The extended period
of alloantibody persistence before AMR detection is similar
to the lag reported in other studies between de novo
alloantibody appearance and rejection. We suggest that
perhaps certain minimum conditions must be met in order
to initiate alloantibody-mediated tissue damage. Perhaps
alloantibody must be composed of complement ﬁxing
isotypes at some minimal level in order to show lytic activity.
Similarly, perhaps donor HLA expression must exist at some
minimal density in order to be an adequate target.
Table 5|Pretransplant antibody profiles between group II
patients who did or did not experience AMR
Without AMR With AMR P-value
1. T-FCXM (channels) 94±49 141±48 0.5
2. B-FCXM (channels) 193±29 117±25 0.07
3. T-PRA (%) 56±23 64±13 0.7
4. B-PRA (%) 11±84 9 ±14 0.1
5. DSA MFI±s.d.
Class I 5601±3601 5950±1598 0.9
Class II 4376±1376 4978±938 0.8
6. Total non-DSA MFI±s.d.
Class I 86,070±84,080 63,720±27,800 0.7
Class II 15,120±12,870 39,250±15,040 0.4
Abbreviations: AMR, antibody-mediated rejection; DSA, donor-specific antibody;
FCXM, flow cytometric crossmatch; MFI, mean fluorescent intensity; PRA, panel-
reactive antibody.
Half the patients in group II experienced AMR and had a high graft failure rate
mediated by chronic rejection. The other half did not experience AMR and
demonstrated excellent long-term graft survival without evidence of CR. Group II
was partitioned into patients who did or did not experience AMR and their
preoperative antibody characteristics were compared. Most patients had only one
class I or II DSA. In the few patients with two DSAs against either class I or II, the MFI
is the strength index of the immunodominant specificity instead of the cumulative
strength. Non-DSA MFIs are a cumulative value derived by combining the MFIs for
all of the non-DSAs into a single cumulative value.
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events (like cellular rejection or infection) or nonimmune-
mediated allograft damage may boost inadequate alloanti-
body/donor antigen presentation and trigger rejection. We
suggest that if certain minimal conditions are not met, then
AMR does not occur, and maintaining high levels of DSA
and non-DSA appears clinically irrelevant at least for the
short term. On the other hand, AMR with persistent
alloantibody must create a smoldering rejection that is
difﬁcult to completely eradicate and upon rebound leads to
chronic disease. It is hoped that early detection would
facilitate AMR reversal. As this study was a blinded protocol
in which alloantibody tests were not reported, medical
intervention was based upon clinical dysfunction and thus
the earliest intervention was not possible.
The heightened sensitivity of the FCXM relative to
cytotoxic crossmatching has always generated controversy
concerning its relevance and concerns that some reactions are
falsely positive. In this study, false-positive FCXMs are
unlikely as we only included patients for analysis when the
preoperatively positive FCXM reactions were validated by
identiﬁable DSA. Similar to a recent report, we found that
use of single antigen bead testing by luminometry detected
DSA in virtually all patients with positive FCXM.
30
Our goal was to develop a post-transplant monitoring
protocol that was clinically informative and manageable from
a laboratory perspective. We focused on the patient group
most problematic to this center; the presensitized patients
with preoperatively positive FCXM. We identiﬁed two
distinct post-transplant alloantibody proﬁles that exhibited
different clinical outcomes. Identiﬁcation of patients at
greater risk of CR should facilitate earlier diagnosis.
The study results allow us to consider strategies to alter
the post-transplant course of patients with persistently
positive FCXM and DSA. One strategy would be to avoid
transplanting patients with positive FCXM and high levels of
DSA. However, complete avoidance would deny transplants
to the majority of patients who will develop a group I proﬁle
that unfortunately cannot be predicted pretransplant. If
transplantation proceeds, preemptive immunomodulation
(intravenous immunoglobulin, plasmapharesis, rituximab,
Velcade) at the time of transplant might promote antibody
depletion in patients who would develop a group II pattern.
Perhaps drug tapering protocols should be reconsidered in
patients with group II proﬁle. We feel longitudinal monitor-
ing is more effective than testing only when there is evidence
of graft dysfunction. Implementing protocol biopsies with
C4d staining would be informative. Antibody persistence or
elevation coupled with rising serum creatinine or histological
changes in the graft should be treated aggressively. Patients
with persistent alloantibody who experience AMR would
likely beneﬁt from antibody-depleting therapies (perhaps
Velcade and rituximab) to reduce or eliminate alloantibody
burden that might minimize AMR recurrence. Last, alloanti-
body monitoring should continue beyond 1 year for patients
with persistent antibody.
PATIENTS AND METHODS
Patients
A total of 308 patients underwent renal transplantation. All
had negative T and B cytotoxic crossmatches. FCXM was
performed before transplant. Excluding patients who had
undergone desensitization, 69 patients (22%) elaborated a
positive preoperative FCXM. For these patients, blood was
collected quarterly during the ﬁrst post-transplant year. Serial
specimens were unavailable for eight patients who were
excluded from subsequent analysis. Clinical outcome for the
remaining 61 patients was obtained from chart review.
Immunosuppression consisted of thymoglobulin (1.5mg/kg
daily for 4 days), SoluMedrol (1g at the day of transplant,
500mg on day 1, 60mg on day 2, tapered 5mg/day until
20mg/day, then tapered 5mg each month to 10mg/day),
mycophenolate mofetil (1g b.i.d.), and tacrolimus (0.1mg/kg
daily). Graft failure was deﬁned as return to dialysis. Deaths
with functioning graft were censored. Protocol biopsies were
not performed. Biopsies were done for clinical indications (for
example, serum creatinine increased 425% above baseline,
nephrotic range proteinuria, delayed graft function). Rejec-
tions were biopsy proven with histological classiﬁcation
following Banff ’97 criteria with updates.
28 AMR was based
upon histological ﬁndings of peritubular capillaries ﬁlled with
polymorphonuclear cells, C4d-positive stain in peritubular
capillaries (staining available starting 2007), histological
evidence of endothelialitis with positive FCXM, and/or ﬁnding
of DSAs. CR was identiﬁed by interstitial ﬁbrosis, ﬁbrointimal
arterial hyperplasia of arterioles, tubular atrophy and glomer-
ulosclerosis, or membranoproliferative glomerular changes.
AMR was treated with alternate day Cytogam and plasma-
pheresis. The study was conducted as a blinded investigation.
The results were not reported and did not inﬂuence clinical
management. All practices conformed to the institutional
review board guidelines for the protection of human subjects.
T- and B-FCXM
Multicolor FCXM was performed as previously described.
27,29
Channels shifts X50 were considered positive for T-FCXM
and B-FCXM.
Solid-phase testing
Pretransplant panel-reactive antibody was determined using
FlowBeads (One Lambda, Canoga Park, CA). Because various
techniques for speciﬁcity determination were used through-
out the years, data were not comparable. Therefore, to make
data comparable and more sensitive, we (1) retested donor
HLA using SSP (One Lambda) to identify minor histocom-
patibility antigens (Cw, DP) not determined originally and
(2) retested serums collected pretransplant and 6 and 12
months post transplant using one lot of single antigen bead
assay on Luminex platform. Speciﬁcities and mean ﬂuor-
escent intensities were determined following the manufac-
turer’s instructions (GenProbe, San Diego, CA). DSAs are
speciﬁcities against donor HLA antigens. Non-DSAs are
speciﬁcities directed against HLA antigens other than the
1136 Kidney International (2011) 79, 1131–1137
original article PM Kimball et al.: Post-transplant alloantibody surveillancedonor’s. Positive FCXM in the absence of anti-HLA
speciﬁcities were considered non-HLA antibodies.
Statistics
Results were analyzed using Kaplan–Meier survival curve,
two-way t-tests, and w
2 test using Graphpad Prism Software
(Graphpad Software, San Diego, CA). Signiﬁcance was
deﬁned as Pp0.05.
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